Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts-Reference-Cited by-同舟云学术

Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts

Published:2015-06-23 Issue:9 Volume:7 Page:1104-1118
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Kemper Kristel¹,Krijgsman Oscar¹,Cornelissen‐Steijger Paulien¹,Shahrabi Aida¹,Weeber Fleur¹,Song Ji‐Ying²,Kuilman Thomas¹,Vis Daniel J³,Wessels Lodewyk F³,Voest Emile E¹,Schumacher Ton NM⁴,Blank Christian U⁴,Adams David J⁵,Haanen John B⁴,Peeper Daniel S¹

Affiliation:

1. Division of Molecular Oncology The Netherlands Cancer Institute Amsterdam The Netherlands

2. Division of Experimental Animal Pathology The Netherlands Cancer Institute Amsterdam The Netherlands

3. Computational Cancer Biology The Netherlands Cancer Institute Amsterdam The Netherlands

4. Division of Immunology The Netherlands Cancer Institute Amsterdam The Netherlands

5. Experimental Cancer Genetics Wellcome Trust Sanger Institute Hinxton Cambridgeshire UK

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201404914

Reference42 articles.

1. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

2. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy

3. Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients

4. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

5. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-derived melanoma models;Pathology - Research and Practice;2024-07

2. Patient-derived skin tumor organoids with immune cells respond to metformin;Cell Organoid;2024-05

3. Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research;Frontiers in Cell and Developmental Biology;2024-04-04

4. BRAF — a tumour-agnostic drug target with lineage-specific dependencies;Nature Reviews Clinical Oncology;2024-01-26

5. Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells;Cancers;2024-01-22